LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (Lansoprazole, Amoxicillin and Clarithromycin) Nursing Considerations

What is the generic name?

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

What is the Trade Name for LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN?

Lansoprazole, Amoxicillin and Clarithromycin

What are the Indications for LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN?

• INDICATIONS AND USAGE H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence The components in lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg (lansoprazole, amoxicillin, and clarithromycin) are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg and other antibacterial drugs, lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

References: https://open.fda.gov/